JW Asset Management LLC Makes New Investment in Urogen Pharma $URGN

JW Asset Management LLC bought a new position in Urogen Pharma (NASDAQ:URGN) in the 3rd quarter, HoldingsChannel.com reports. The firm bought 20,000 shares of the company’s stock, valued at approximately $813,000. Urogen Pharma accounts for 0.3% of JW Asset Management LLC’s holdings, making the stock its 19th biggest position.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Urogen Pharma in the 2nd quarter valued at $117,814,000. Jefferies Financial Group Inc. acquired a new position in shares of Urogen Pharma in the 2nd quarter valued at $80,947,000. Bank of America Corp DE acquired a new position in shares of Urogen Pharma in the 2nd quarter valued at $17,506,000. Rice Hall James & Associates LLC bought a new position in shares of Urogen Pharma during the 2nd quarter worth about $11,064,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of Urogen Pharma during the 2nd quarter worth about $9,288,000. 91.29% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Urogen Pharma news, insider Mark Schoenberg sold 871 shares of the business’s stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $42.92, for a total value of $37,383.32. Following the transaction, the insider directly owned 59,882 shares in the company, valued at $2,570,135.44. The trade was a 1.43% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Jason Smith sold 1,519 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $42.54, for a total transaction of $64,618.26. Following the sale, the general counsel directly owned 53,141 shares in the company, valued at $2,260,618.14. This represents a 2.78% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 65,269 shares of company stock worth $3,037,646 in the last quarter. 4.80% of the stock is owned by corporate insiders.

Urogen Pharma Trading Up 1.1%

Urogen Pharma stock opened at $26.39 on Friday. The stock has a fifty day moving average price of $37.38 and a two-hundred day moving average price of $31.65. Urogen Pharma has a 52-week low of $16.50 and a 52-week high of $50.81.

Urogen Pharma (NASDAQ:URGN) last issued its earnings results on Wednesday, November 4th. The company reported ($0.03) EPS for the quarter, missing the consensus estimate of $0.11 by ($0.14). The firm had revenue of $89.00 million for the quarter, compared to the consensus estimate of $89.92 million. On average, equities research analysts predict that Urogen Pharma will post -0.36 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on URGN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Thursday, October 15th. HC Wainwright reissued a “buy” rating and issued a $75.00 price target on shares of Urogen Pharma in a research report on Monday, October 19th. UBS Group restated an “outperform” rating on shares of Urogen Pharma in a research note on Thursday, November 5th. TD Cowen lifted their price objective on Urogen Pharma from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Finally, Guggenheim lowered their price objective on Urogen Pharma from $58.00 to $56.00 and set a “buy” rating on the stock in a research note on Thursday, November 5th. Eight analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $53.38.

Urogen Pharma Company Profile

UroGen Pharma Ltd. is a biopharmaceutical company focused on developing and commercializing treatments for cancers of the urinary tract. Its work centers on therapies delivered directly to the urinary system, including treatments for certain forms of urothelial cancer. The company’s products include Jelmyto, a mitomycin-based treatment delivered to the upper urinary tract for adults with low-grade upper tract urothelial cancer, and Zusduri, a mitomycin-based treatment for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer.